Loading
A phase 3 trial of Repotrectinib and Crizotinib in non-small-cell lung cancer, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) is a phase 3 interventional study registered as NCT06140836 by Bristol-Myers Squibb, with 190 participants enrolled, started 2023-12-21 and due to reach its primary completion in 2026-03-13. Interventions recorded: Repotrectinib and Crizotinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ROS1-positive non-small-cell lung cancer, Crizotinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Repotrectinib, Bristol Myers Squibb, Small-molecule kinase inhibitors and the tag pipeline.
Shares Repotrectinib, ROS1-positive non-small-cell lung cancer, Bristol Myers Squibb, Small-molecule kinase inhibitors and the tag pipeline.
Shares Bristol Myers Squibb, Non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/